Webinar | Direct-to-Biology, a powerful approach to accelerate hit finding: Concept and application to drug discovery programs

Presenters: Joe Mason, Associate Principal Scientist and Nick Bland, Group Leader

In the first of our Drug Discovery webinar series, we discuss Direct-to-Biology (D2B) and its potential to accelerate hit finding. The series is hosted by One Nucleus.

Catch up on the webinar on demand or sign up to be the first to hear about future webinars.

Direct-to-Biology (D2B) has emerged as a powerful method to find hit compounds and build Structure Activity Relationships (SAR) for drug discovery programs. During this webinar, we cover the concept of D2B and how and when it can be applied to drug-discovery programs. A case study demonstrates the potential of this approach.

Agenda:

• Introduction from One Nucleus and Domainex
• Presentation from Joe Mason, Associate Principal Scientist and Nick Bland, Group Leader, Domainex
• Q&A and Close